Search by Drug Name or NDC
NDC 59148-0045-80 ABILIFY MAINTENA Details
ABILIFY MAINTENA
ABILIFY MAINTENA is a KIT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Otsuka America Pharmaceutical, Inc.. The primary component is .
MedlinePlus Drug Summary
Aripiprazole extended-release injection (Abilify Maintena, Aristada, Aristada Initio) is used alone or in combination with other aripiprazole preparations to treat schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Aripiprazole extended-release injection (Abilify Maintena) is also used for the ongoing treatment of people with bipolar I disorder (manic-depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Aripiprazole is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.
Related Packages: 59148-0045-80Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Aripiprazole Injection
Product Information
| NDC | 59148-0045 |
|---|---|
| Product ID | 59148-045_8f12a17b-6fbd-4db0-bea1-867f1f2b7d7b |
| Associated GPIs | 5925001500E430 |
| GCN Sequence Number | 073298 |
| GCN Sequence Number Description | aripiprazole SUSER SYR 300 MG INTRAMUSC |
| HIC3 | H7X |
| HIC3 Description | ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED |
| GCN | 37681 |
| HICL Sequence Number | 024551 |
| HICL Sequence Number Description | ARIPIPRAZOLE |
| Brand/Generic | Brand |
| Proprietary Name | ABILIFY MAINTENA |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | aripiprazole |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | KIT |
| Route | n/a |
| Active Ingredient Strength | n/a |
| Active Ingredient Units | n/a |
| Substance Name | n/a |
| Labeler Name | Otsuka America Pharmaceutical, Inc. |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA202971 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 59148-0045-80 (59148004580)
| NDC Package Code | 59148-045-80 |
|---|---|
| Billing NDC | 59148004580 |
| Package | 1 KIT in 1 CARTON (59148-045-80) * 1.5 mL in 1 SYRINGE * 5 mL in 1 SYRINGE |
| Marketing Start Date | 2014-10-08 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 2018.09 |
| Pricing Unit | EA |
| Effective Date | 2024-01-15 |
| NDC Description | ABILIFY MAINTENA ER 300 MG SYR |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |